Hepatitis C elimination across drug and alcohol services
This initiative is led by the NHS Addictions Provider Alliance and is commissioned by the NHS England Hepatitis C Elimination Programme. Additionally the work is supported by a joint working agreement with Gilead Sciences who do not currently provide funding to Hep C U Later.
The aim to micro-eliminate hepatitis C within the drug and alcohol services of the NHS Addictions Provider Alliance is well underway with many services declaring micro-elimination.
More about our work in drug and alcohol services
Hep C U Later works extensively across drug and alcohol services nationally, through collaborating with the NHS Trusts within the NHS Addictions Provider Alliance and providing guidance and support on:
- Minimising data recording anomalies or issues with clinical recording systems
- Reflecting data back on dashboards
- Reviewing and improving testing and treatment pathways
- Linking stakeholders
- Supporting innovative work such as clinical outreach vans and pilot projects
- Providing bespoke training, webinars and forums
- Supporting with testing and treatment events
- Supporting services to use GeneXpert (Cepheid) machines
- Strategic planning
- Communications and marketing strategy
- Awareness and engagement campaigns
- Providing benchmarking work
- Providing resources to support staff and service users
- Using quality improvement methodology
To read more about what we’ve achieved take a look at our Impact Report.
Joint Working Agreement Partners
NHS Addiction Provider Alliance Trusts involved with Hep C U Later
Working collaboratively
Hep C U Later collaborates with multiple national partners in the fight to micro-eliminate hepatitis C such as the Hepatitis C Trust, UKHSA, Operational Delivery Networks (ODNs), and Hepatology departments.
Gilead Sciences lead the Hep C Drug Treatment Service Provider Forum which brings together national BBV leads from across the drug treatment sector. The NHS APA is represented by Hep C U Later and the group consists of national Blood-Borne-Virus (BBV) leads from across the third sector. Within this group, we look to standardise work to reduce inequity and continually increase the quality of hepatitis C-related interventions.
We combine our efforts to promote joint awareness campaigns and learn from each other. Together, the Hepatitis C Drug Treatment Service Provider Forum has been shortlisted for many awards and in 2023 won the HSJ Best Healthcare Analytics Project for the NHS award.